Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO)

INTRODUCTION: Somatostatin analogues are used to treat symptoms and slow tumour progression in patients with neuroendocrine tumours (NETs) and carcinoid syndrome and to reduce hormone secretion and pituitary tumour volume in patients with acromegaly. A new syringe for lanreotide autogel/depot (LAN)...

Descripción completa

Detalles Bibliográficos
Autores principales: Adelman, Daphne, Truong Thanh, Xuan-Mai, Feuilly, Marion, Houchard, Aude, Cella, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140743/
https://www.ncbi.nlm.nih.gov/pubmed/32157626
http://dx.doi.org/10.1007/s12325-020-01255-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140743/
https://www.ncbi.nlm.nih.gov/pubmed/32157626
http://dx.doi.org/10.1007/s12325-020-01255-8

Ejemplares similares